AN 788

Drug Profile

AN 788

Alternative Names: AN-788; NSD788

Latest Information Update: 14 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeuroSearch
  • Developer Aniona; Saniona
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Major depressive disorder
  • Discontinued Anxiety disorders

Most Recent Events

  • 14 Apr 2016 AN 788 is still in phase I development for Major depressive disorder in USA
  • 14 Apr 2016 AN 788 is still available for licensing as of 14 Apr 2016.
  • 20 Mar 2014 Aniona is now called Saniona
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top